HORSHOLM, Denmark--(BUSINESS WIRE)--Highlights LifeCycle Pharma A/S (OMX:LCP) reported a net loss of DKK 140.3 million for the first half of 2008, compared to a net loss of DKK 85.7 million for the same period in 2007. This is in line with the outlook for 2008 which was announced in the Q1 2008 report May 14, 2008. During the first half of 2008, LifeCycle Pharma recognized DKK 10.9 million in revenue compared to DKK 7.0 million in the same period of 2007. Revenue consists of payments under the company’s collaboration agreements, and incurred royalty payments relating to Fenoglide sale.
